Clofazimine in the Treatment of Pulmonary Mycobacterium Avium Complex (MAC)
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the clinical effectiveness and safety of clofazimine
when used to treat Mycobacteria avium complex (MAC) lung disease.
Funding Source - FDA OOPD
Phase:
Phase 2
Details
Lead Sponsor:
Oregon Health and Science University
Collaborators:
FDA Office of Orphan Products Development National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID) National Jewish Health The University of Texas Health Science Center at Tyler University of Chicago